[1]
E. Salinas Alva, E. Poquioma Rojas, and R. Hinojosa Ramírez, “Management of hormonal therapy for the treatment of advanced hormone-dependent prostate cancer: A pharmacoeconomics assessment of the use of Degarelix – Firmagon® compared to generic triptorelin”, Acta Med Peru, vol. 28, no. 4, pp. 188-193, May 2024.